期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

药物经济学与“me -too”药物研发 被引量：1

Pharmacoeconomics and "me-too" Drug Research and Development
原文传递
导出
摘要 目的:探讨药物经济学如何应用于"me -too"药物研发过程中。方法:首先探讨"me -too"药物目前所处的境况,即对"me -too"药物研发的优势和可能付出的代价进行分析,指出药物经济学研究在"me -too"药物研发过程中应用的必要性,并阐述药物经济学在"me -too"药物研发过程中的应用阶段,应用时如何进行方法的选取及应用时可能出现的问题与对策。结果与结论:药物经济学能够促进"me -too"药物研发的合理性。 OBJECTIVE： To discuss how can the pharmacoeconomics be applied in ＂me - too＂ drug research and development .METHODS：The current situation of ＂me - too＂ drugs,i .e .the advantageous and disadvantageous of ＂me-too＂ drug research and development was discussed.Then, the necessity and the application stage of pharmacoeconomics in ＂me-too＂ drug research and development, and issues regarding the option of pharmacoeconomic evaluation methods as well as the possible problems and the countermeasures in the application were addressed.RESULTS ＆ CONCLUSION： Pharmacoeconomics can help promote the rationality of ＂me-too＂ drug research and development.
作者 孙继香 李海涛 夏慧 李士雪
机构地区 山东大学齐鲁医院中医科 山东大学卫生管理与政策研究中心 山东大学公共卫生学院
出处 《中国药房》 CAS CSCD 北大核心 2007年第35期2725-2728,共4页 China Pharmacy
关键词 药物经济学 “me-too”药物 研发 Pharmacoeconomics ＂me - too＂ drug Research and development
分类号 R956 [医药卫生—药学]
  • 相关文献

参考文献12

  • 1Lu ZJ, Comanor WS.Strategic pricing of new pharmaceuticals[J].Rev Econ Star, 1998,80(1) : 108.
  • 2Lee TH. ‘Me - too' products: friend or foe? [J]. N Engl J Med ,2004,350(15) : 1 586.
  • 3DiMasi JA, Paquette C. The economics of follow - on drug research and development: Trends in entry rates and the timing of development [J].Pharmacoeconomics, 2004,22(Suppl 2) : 1.
  • 4Ekelund M,Persson B.Pharmaceutical pricing in a regulated market [J]. Rev Econ Stat, 2003,85(2) : 298.
  • 5Azoulay P .Do pharmaceutical sales respond to scientific evidence? [J].J Econ Manage Strategy, 2002,11(4) : 551.
  • 6Hollis A .Comment on “The economics of follow- on drug research and development: trends in entry rates and the timing of development” [J] .Pharmacoeconomics ,2005,23(12) : 1 187.
  • 7Lichtenberg F,Philison T.The dual effects of intellectual property regulations: within and between patient competition in the US pharmaceuticals industry[J] .J Law Econ , 2002,45(2) : 643.
  • 8Olson MK .Are novel drugs more risky for patients than less novel drugs? [J].J Health Econ , 2004,23(6): 1 135.
  • 9杨莉,胡善联,宫印成.药物经济学评价在卫生决策中的国际应用[J].中国药房,2004,15(6):347-350. 被引量：34
  • 10Masi D .The price of innovation:new estimates of drug development costs [J]. Journal of Health Economics, 2003,22(2) : 151.

二级参考文献21

  • 1陈英耀.OECD国家卫生费用和卫生服务的趋势[J].中国卫生资源,2001,4(3):141-144. 被引量：10
  • 2Drummond,MF.The role of economic evaluation in the pricing and reimbursement of medicines[J] .Health Policy, 1997,40:199.
  • 3Ministry of health, welfare and sports. The Future of Health Insurance System [ S ]. Dutch, 1999.
  • 4Ziekenfondsraad.Dutch Guidelines for Pharmacoeconomic Research [ S]. Ziekenfondsraad amst elveen, March,1999.
  • 5Tobin H,Tumer N,Wyatt G.Pharmacoeconomics 2002:A Concise Guide [ S ]. PPR Communications, Ltd., Cambridge, UK. 2002.
  • 6Torrance G.Current experience with guidelines for economic evaluation in Canada[J ]. Drug Information Journal, 1996,30: 507.
  • 7Glennie JL,Torrance GW,Baladi JF,et al .The revised Canadian guidelines for the economic evaluation of pharmaceuticals [ J ] . Pharmacoeconom ics, 1999,15(5): 459.
  • 8Anis AH,Gagnon Y.Using economic evaluations to make formulary coverage decisions: so much for guidelines[J]. Pharmacoeconomics, 2000,18(1): 55.
  • 9Kanavos P.Pharmaceutical Pricing and Reimbursement in Europe- 2002[ S ].PJB Publications Ltd. 2002.
  • 10National Institute for Clinical Excellence. Technical Guidance for Manufacturers and Sponsors on Making a Submission to a Technology Appraisal [S] .March,2001

共引文献36

同被引文献1

引证文献1

二级引证文献1

中国药房
2007年 第35期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部